Sodium naproxen versus sodium diclofenac in cancer pain control.
In a single-blind random study, simultaneously carried out by five Pain Therapy and Palliative Care Centres, the analgesic power and side-effects of sodium naproxen (CAS 26159-34-2) and sodium diclofenac (CAS 15307-86-5) by mouth were compared in a group of 100 advanced cancer patients. The patients complained of somatic and/or visceral pain and were treated with non-steroid anti-inflammatories as required. The dose administered amounted to 550 mg every 12 h for sodium naproxen and to 100 mg every 12 h for sodium diclofenac. The study stressed the similar analgesic effect of the two drugs--pain intensity and duration decreased by half in the first week of treatment--and a comparatively low morbidity rate.
Ventafridda
V
V
Italian National Cancer Institute, Milan.
Toscani
F
F
Tamburini
M
M
Corli
O
O
Gallucci
M
M
Gottlieb
A
A
Speranza
R
R
De Conno
F
F
D000368:Aged; D004008:Diclofenac / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D009288:Naproxen / Q000009:adverse effects / Q000627:therapeutic use*; D009369:Neoplasms / Q000503:physiopathology*; D010148:Intractable Pain / Q000188:drug therapy*; D011897:Random Allocation; D016037:Single-Blind Method
D004008:Diclofenac; D009288:Naproxen